Squamous Dysplasia—The Precursor Lesion for Esophageal Squamous Cell Carcinoma

Philip R. Taylor¹, Christian C. Abnet², and Sanford M. Dawsey²

Abstract

Esophageal squamous cell carcinoma (ESCC) accounts for 80% of all esophageal cancers worldwide, and esophageal squamous dysplasia (ESD) is the only histopathology that predicts the development of ESCC. The prevalence of ESD parallels rates of invasive ESCC and is typically found in 25% or more of adults above the age of 35 years in populations in north central China, where risk for ESCC is among the highest in the world. Results of chemoprevention and early detection studies to prevent progression of ESD suggest that these approaches, coupled with emerging endoscopic therapies, offer promise for the prevention of esophageal cancer mortality in high-risk populations. Future research on ESD and ESCC should focus on finding additional modifiable risk factors and on identifying biomarkers to incorporate into early detection strategies. Cancer Epidemiol Biomarkers Prev; 22(4); 540–52. ©2013 AACR.

Introduction and Historical Context

Rates

Esophageal cancer is the eighth most common cancer and the sixth most common cause of cancer-related death in the world, with an estimated 482,000 new cases and 407,000 deaths in 2008 (1). There are 2 main histopathologic types of esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). EAC, due largely to gastroesophageal reflux disease and obesity, has increased dramatically in the past 30+ years and is now the predominant type in the United States and most other Western countries. Worldwide, however, ESCC dominates with 80% of all cases, due largely to high rates in many developing countries. China, with its high rates and large population, accounts for over half of all esophageal cancer–related deaths in the world and nearly all are ESCC. High rates of esophageal cancer are found along geographic belts, one following the ancient Silk Road from north central China through the central Asian republics to northern Iran, and one from eastern to southern Africa (Fig. 1). This minireview will focus only on precursors of ESCC.

Precursors

Although early studies conducted in high-risk areas suggested that esophagitis was a precursor for ESCC (2), subsequent studies have shown that dysplasia is the only histopathology that predicts the development of ESCC.

Histologic and Molecular Characterization

Histologic characterization

Histologic criteria for the ESCC precursor lesion, esophageal squamous dysplasia (ESD), were initially described in the 1970s (6–9) and modified in the 1980s based on experience in China (10). Squamous dysplasia requires the presence of nuclear atypia (enlargement, pleomorphism, and hyperchromasia), loss of normal cell polarity, and abnormal tissue maturation without invasion of epithelial cells through the basement membrane. Compared

Qiu and Yang (3) were the first to provide evidence that esophagitis alone was nonspecific and dysplasia was a precancerous state, but the most definitive assessment of risk from squamous esophageal histology has come from follow-up of 682 participants in the Linxian Dysplasia Nutrition Intervention Trial (NIT), who participated in an endoscopy survey in 1987 (4). A comparison of initial biopsy diagnoses with the occurrence of ESCC over the subsequent 3.5 years showed that only dysplasia predicted development of ESCC and that increasing grades of dysplasia predicted increased risk: compared with normal, relative risks [95% confidence intervals (CI)] were 2.2 (0.7–7.5) for mild dysplasia, 15.8 (5.9–42.2) for moderate dysplasia, 72.6 (29.8–176.9) for severe dysplasia, 22.9 (6.7–78.0) for dysplasia not otherwise specified, and 62.5 (24.1–161.9) for carcinoma in situ (CIS). Of note, dysplasia not otherwise specified (NOS) and moderate dysplasia risks were similar, as were risks for carcinoma in situ and severe dysplasia. Further follow-up of this same endoscopic cohort for a total of 13.5 years corroborated the previous risk estimates and provided more precise quantification. Over the full follow-up period, ESCC developed in 8% of participants with normal histology but 24% with mild dysplasia, 50% with moderate dysplasia, 74% with severe dysplasia, 58% with dysplasia NOS, and 75% with carcinoma in situ (Fig. 2; ref. 5).

Authors’ Affiliations: ¹Genetic Epidemiology Branch and ²Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland

Corresponding Author: Philip R. Taylor, National Cancer Institute, NIH, EPS, 6120 Executive Blvd, Rm 7006, Bethesda, MD 20892. Phone: 301-594-2932; Fax: 301-402-4489; E-mail: ptaylor@mail.nih.gov
doi: 10.1158/1055-9965.EPI-12-1347
©2013 American Association for Cancer Research.
with normal (Fig. 3A), in mild dysplasia these abnormalities are confined to the lower third of the epithelium (Fig. 3B), whereas in moderate dysplasia they are present in the lower two thirds of the epithelium (Fig. 3C), and in severe dysplasia they also involve the upper third of the epithelium (Fig. 3D). Full thickness involvement of the epithelium, called carcinoma in situ by some, is considered synonymous with severe dysplasia based on their similar histologic appearance and risk of progression to invasive ESCC. A final category, dysplasia NOS, indicates that dysplasia is present but cannot be graded accurately because of poor tissue orientation or artifact and has progression risk approximating that of moderate dysplasia; rebiopsy to accurately grade the dysplasia would be necessary to define cancer risk.

**Molecular characterization**

Numerous molecular alterations in ESCC tumors have been identified. Among them, TP53 alterations are the most common. One study of 56 ESCC cases from north central China found at least 1 genetic alteration in TP53 in 96% of the tumors studied, including mutations (77%), allelic loss within the gene (73%), and/or LOH at the TP53 microsatellite marker (80%); and three quarters of the cases had 2 or more such alterations (11). In a study conducted in northeastern Iran, 90% of the 119 ESCC
cases sequenced), frequent mutations in ESCC occurred in recently, whole-exome sequencing found that ESCCs had as gain- and loss-of-function candidates in ESCC (14). Methylation; ref. 13. In addition, RNA array expression of zygous deletion, 47% microsatellite LOH, 18% aberrant methylation; ref. 13). In addition, RNA array expression studies have found numerous other dysregulated genes as gain- and loss-of-function candidates in ESCC (14). Recently, whole-exome sequencing found that ESCCs had an average of 83 mutations per tumor, and that the most frequent mutations in ESCC occurred in TP53 (92% of the 12 cases sequenced), NOTCH1 (33%), NOTCH3 (25%), and FBXW7 (17%; ref. 15). Premalignant lesions of the squamous esophagus have been studied much less than ESCC tumors. The most common molecular-oriented approach applied to premalignant lesions thus far has been immunohistochemical studies of the expression of 1 or more candidate proteins. Numerous studies have shown overexpression of p53 protein in squamous dysplasia compared with normal tissue. In one study, for example, 92% of 12 dysplasia samples and 0% of 14 normal tissue samples obtained from the resection specimens of 44 ESCC cases were p53 positive, as were all 5 dysplasia biopsies and 50% of 6 normal biopsies taken from 51 cancer-free patients (16). Other proteins shown to have increased expression in dysplasia include CD44 (17); TGF-β1 (positive in 81% of dysplasia vs. 37% of normal samples; ref. 18); PCNA (positive in 78% of dysplasia vs. 55% of normal; refs. 19, 20); FADD, CDC23B, fascin, CK14, LAMC2, and SPARC (21); p16 (positive in 88% of dysplasia vs. 10% of normal), p15 (positive in 73% of dysplasia vs. 0% in normal), p14 (positive in 100% of dysplasia vs. 15% of normal; ref. 22); and PTCH1 (positive in 21% of dysplasia vs. 0% of normal; ref. 23). Decreased expression in dysplasia compared with normal has been observed for TGF-β receptor II (81% positive in dysplasia vs. 98% positive in normal; ref. 18); esophagin (positive in 9% of dysplasia vs. 53% of normal; ref. 20); and Fas, caspase-8, CK4, annexin 1 (21). Nucleic acid–based studies of precursors have shown increased allelic loss (pointing to potential tumor suppressor gene inactivation sites) with increasing grade of dysplasia at a wide variety of microsatellite loci (i.e., 3p, 4p, 5q, 6p, 9p, 9q, 10p, 11p, 13q, and 17p; refs. 24–27). Mutation studies in esophageal squamous precursors have been limited to TP53, where missense mutations were evident early in esophageal carcinogenesis (4 of 11 samples with dysplasia vs. 1 of 3 normal epithelia; ref. 28). Several studies have evaluated promoter hypermethylation in candidate genes in esophageal precursors (29–32). Most of these studies showed little or no hypermethylation in normal tissue, with progressively more hypermethylation as morphology advanced toward ESCC. Of the 30+ different genes evaluated, only p16INK4a was examined in all 4 studies, and it showed hypermethylation in from 4% to 38% of lesions with dysplasia. While a reasonable number of studies have reported molecular characteristics in esophageal squamous premalignancy, these studies often used different designs and analytic approaches, few studies examined the same targets, objective and quantitative assessments were not typical, and sample sizes were generally small. Taken together, these differences limit the comparability and overall conclusions that can be drawn from the studies. More recently, high throughput genome-wide methods in the analysis of patterns of RNA expression (33–35), differential methylation, and gene copy number have shown promise in distinguishing patients with and without high-grade squamous dysplasia (36). Real progress in identifying the changes driving esophageal squamous carcinogenesis will require the comprehensive application of new high throughput technologies, including whole-genome sequencing, RNA sequencing, and global epigenomics, in addition to objective, quantified characterization of protein expression, all analyzed in a fully integrated manner. Genetic susceptibility to ESCC is evidenced by the identification of tylosis, a rare autosomal dominant skin disorder characterized by hyperkeratosis of the palms and soles reported in the literature in 3 families (37), and recent findings from genome-wide association studies (GWAS), where up to 17 loci have been associated with ESCC risk in Chinese populations (38–41). While cumulative risk of ESCC to age 70 years in family members with tylosis is estimated at more than 90%, risk associated with alleles identified in GWAS to date is modest (e.g., the per allele
OR for PLCE1 is 1.34). Experience with breast cancer suggests that even the combination of all GWAS hits together is unlikely to demonstrably improve clinical risk prediction (42). There are, as yet, no published studies on the genetics or genomics of susceptibility to ESD.

**Descriptive Epidemiology and Etiology**

**Etiology of ESCC**

While all ESCCs share a common histology, etiologically there are 2 distinctly different ESCC diseases. ESCC occurs in developed countries at rates that are low to moderate, and etiology there can be attributed almost entirely to exposure to alcohol and tobacco (43). In contrast, in the economically less developed countries in eastern and central Asia and eastern and southern Africa, where rates of ESCC are the highest in the world, alcohol and tobacco exposure have little or no role. The Taihang Mountain region of north central China has the highest ESCC incidence in China, with rates in women that are nearly as high as in men despite the fact that very few women use tobacco or drink alcohol (44, 45). Similarly, northern Iran has high rates, yet alcohol is consumed by less than 2% of the population due to religious proscription (46). Studies in high-risk regions suggest that exposure to carcinogens such as polycyclic aromatic hydrocarbons (47), opium (46), poor nutrition (48–52), and thermal damage (45, 53) are major risks, whereas tobacco exposure plays only a minor role (44–46). Despite these differences in etiology, both high- and low-rate ESCC share dysplasia as their precursor lesion, and thus approaches to screening and treatment are common to both.

**Prevalence of precursor lesions**

The prevalence of esophageal squamous dysplasia has been documented best in the areas of the world where ESCC rates are highest, specifically in Iran and China, where reports from 11 surveys have been published (Table 1). Dysplasia prevalence has varied from 3% to 38% in these surveys, due in part to differences in the populations (i.e., risk level, age and gender differences, whether or not persons had a prior diagnosis of dysplasia, and the presence of symptoms), endoscopy methods (i.e., use of Lugol’s iodine on the mucosa, number of biopsies taken), and the pathology criteria used (2, 3, 10, 54–59). The earliest surveys found lower rates, most likely due to different pathology criteria and lack of mucosal iodine staining. The 2 surveys from Iran both found 4% prevalence (54, 59), whereas with rare exception, the Taihang Mountain region in China has shown dysplasia prevalences that were much higher, exceeding 20%.

The 5 most recent surveys in north central China reported grades of dysplasia in addition to total dysplasia prevalence (10, 55–58). In these surveys, the most common grade of dysplasia was mild (median, 10.6%; range, 2.6%–14.0%), followed by moderate (7.8%, 0.2%–12.0%), and severe (including CIS; 5.3%, 0.4%–7.4%).

**Risk factors for dysplasia**

The few studies conducted to evaluate risk factors for esophageal squamous dysplasia have all been conducted in the high-risk Taihang Mountain region in China. These studies have focused on known or suspected risk factors for cancer and have not included wide-ranging assessments of risk for esophageal squamous dysplasia associated with other exposures.

A screening study of 724 healthy adults of ages 40 to 65 years from Linxian conducted in 2002 (57) served as the basis for 4 evaluations of risk factors for dysplasia. Among the 720 subjects who underwent endoscopy during this study, the prevalence of risk factors among the 230 subjects with dysplasia was compared with the prevalence among 490 subjects without dysplasia. Questionnaire-based analyses found significantly increased risk for dysplasia among persons who had a positive family history of cancer (OR, 1.57; 95% CI, 1.13–2.18), had higher systolic blood pressure (1.11/10 mm Hg, 1.03–1.19), used a heating stove without a chimney (2.22, 1.27–3.86) and had lost more but not all of their teeth (1.91 for 12–31 vs. <4 teeth lost, 1.17–3.15). Although not quite statistically significant, risk of dysplasia was lower in households with smaller size and higher income (60). Higher serum 25-hydroxyvitamin D concentrations were also associated with increased risk for dysplasia in this endoscopy cohort (OR, 1.86; 95% CI, 1.35–2.62 for high vs. low quartile; ref. 61). Serum pepsinogens (PG) I and II were evaluated in 125 dysplasia cases and 250 sex-matched controls from this same cohort. In this study, PG I levels did not differ between dysplasia cases and noncases, however, the PG I/II ratio showed a strong dose–response relation, with lower PG I/II levels associated with increased risk of dysplasia (OR, 2.12; 95% CI, 1.08–4.18 for low vs. high quartile), consistent with a role for gastric atrophy in the etiology of esophageal dysplasia (62). Finally, the association between HPV and ESCC has been inconsistent (63–68). In precursors, 1 study of HPV DNA in esophageal cells from balloon cytology found no association with dysplasia (69), whereas 2 other studies did observe HPV DNA in dysplasia (70, 71).

An endoscopic survey from Anyang among 7,381 inhabitants evaluated questionnaire-based exposure to tobacco, alcohol, tooth loss, pesticide exposure, preferred food temperature, and water source as potential risk factors in 228 cases (97.5% with dysplasia, 2.5% with ESCC) compared with 6,932 control subjects without ESCC or dysplasia (58). Among these 6 potential risk factors, only water source showed a significant association with dysplasia/ESCC. Subjects with deep wells had lower risk of dysplasia/ESCC than persons with shallow wells (OR, 0.72; 95% CI, 0.54–0.96).

A summary comparison of risk factors evaluated for both ESCC and dysplasia is shown in Table 2. With the exceptions of smoking (a risk for ESCC but not dysplasia) and serum pepsinogens (a risk for dysplasia but not ESCC), the other risk factors studied were concordant for both dysplasia and ESCC.
<table>
<thead>
<tr>
<th>Year reported</th>
<th>Authors (ref no.)</th>
<th>Location</th>
<th>Number</th>
<th>Age, y</th>
<th>Gender</th>
<th>Prior dysplasia</th>
<th>EGD*</th>
<th>Dysplasia</th>
<th>All dysplasia</th>
<th>Invasive ESCC</th>
<th>All dysplasia by gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>1979</td>
<td>Crespi and colleagues (54)</td>
<td>Gonbad, Iran</td>
<td>430</td>
<td>15–70</td>
<td>M+F</td>
<td>None</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>4% NA 5% M 3% F</td>
</tr>
<tr>
<td>1982</td>
<td>Munoz and colleagues (2)</td>
<td>Linxian, PRC</td>
<td>527</td>
<td>25–55</td>
<td>M+F</td>
<td>One-third</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>8% 0.9% 8% M 8% F</td>
</tr>
<tr>
<td>1988</td>
<td>Qiu and Yang (3)</td>
<td>Linxian and Boaixian, PRC</td>
<td>1,043</td>
<td>NA</td>
<td>M+F</td>
<td>Most</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>17% 1.8% 17% M 18% F</td>
</tr>
<tr>
<td>1988</td>
<td>Qiu and Yang (3)</td>
<td>Huixian, PRC</td>
<td>300</td>
<td>35–65</td>
<td>M+F</td>
<td>NA</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>38% 2.7% 37% M 41% F</td>
</tr>
<tr>
<td>1988</td>
<td>Qiu and Yang (3)</td>
<td>Fanxian, PRC</td>
<td>300</td>
<td>35–65</td>
<td>M+F</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>5% 1% 6% M 4% F</td>
</tr>
<tr>
<td>1994</td>
<td>Dawsey and colleagues (10)</td>
<td>Linxian, PRC</td>
<td>300</td>
<td>40–69</td>
<td>M+F</td>
<td>All</td>
<td>No</td>
<td>10.6%</td>
<td>4.6%</td>
<td>5.8% 1.6% 23%</td>
<td>4.6%</td>
</tr>
<tr>
<td>1997</td>
<td>Roth and colleagues (55)</td>
<td>Linxian, PRC</td>
<td>439</td>
<td>50–69</td>
<td>M+F</td>
<td>None</td>
<td>Yes</td>
<td>12.0%</td>
<td>10.0%</td>
<td>6.0% 28%</td>
<td>4.0%</td>
</tr>
<tr>
<td>2004</td>
<td>Lu and colleagues (56)</td>
<td>Cixian, PRC</td>
<td>2,013</td>
<td>40–69</td>
<td>M+F</td>
<td>NA</td>
<td>Yes</td>
<td>8.6%</td>
<td>7.8%</td>
<td>2.6% 2.7% 22%</td>
<td>0.7% 26% M 18% F</td>
</tr>
<tr>
<td>2008</td>
<td>Pan and colleagues (57)</td>
<td>Linxian, PRC</td>
<td>725</td>
<td>50–64</td>
<td>M+F</td>
<td>NA</td>
<td>Yes</td>
<td>14.0%</td>
<td>12.0%</td>
<td>5.0% 32%</td>
<td>0.6%</td>
</tr>
<tr>
<td>2010</td>
<td>He and colleagues (58)</td>
<td>Anyang, PRC</td>
<td>7,381</td>
<td>25–65</td>
<td>M+F</td>
<td>NA</td>
<td>Yes</td>
<td>2.6%</td>
<td>0.2%</td>
<td>0.2% 0.2% 3%</td>
<td>0.1%</td>
</tr>
<tr>
<td>2012</td>
<td>Etemadi and colleagues (59)</td>
<td>Gonbad, Iran</td>
<td>724</td>
<td>NA</td>
<td>M+F</td>
<td>None</td>
<td>Yes</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>4% NA</td>
</tr>
</tbody>
</table>

*EGD, esophagogastroduodenoscopy.

bNA, information not available.
Clinical Perspective and Natural History

Survival

The survival of ESCC is very poor, largely due to late development of symptoms and consequent late diagnosis. The most recent 5-year relative survival rate for esophageal cancer in the Surveillance Epidemiology and End Results (SEER) registries (2001–2007) was 19% (72). In developing countries, however, where most of the ESCC cases occur, survival rates are much lower. A recent study from northeastern Iran reported a 5-year survival rate of 3.4% (73), which is probably a more typical figure in high-risk, low-resource populations. Survival is dramatically dependent on the stage of disease at diagnosis: in SEER (2001–2007), the 5-year survival rates were 37%, 18%, and 3% for localized, regional, and distant disease, and in China, 5-year survival of patients with stage T1 ESCC has been reported to be 86% (74).

The large difference in survival by stage suggests that early detection of precursor lesions and early-stage cancers might offer a chance to significantly reduce mortality. The problem, of course, is how to identify individuals with these early treatable lesions, as virtually all of these people are asymptomatic. Thus, the challenge is to risk-stratify asymptomatic people and then develop an accurate, patient-acceptable, and cost-effective way to screen high-risk groups and find the few individuals who need treatment.

Endoscopic visualization of dysplasia

One way to identify ESD and early ESCC is by endoscopy with Lugol’s iodine staining. Iodine reversibly binds with glycogen, which is abundant in the superficial cells of normal esophageal squamous mucosa but is scant or absent in the rapidly dividing cells of significant esophagitis or dysplasia. Thus, spraying Lugol’s iodine solution on the esophageal mucosa turns normal areas brown but leaves areas of severe esophagitis or dysplasia unstained. These negative image “unstained lesions” (USLs) can be endoscopically targeted for biopsy and, if appropriate, focal endoscopic therapy (Fig. 4). The sensitivity of these USLs for the presence of high-grade (moderate or severe) ESD or early invasive ESCC is very high, around 95% in studies from China (75, 76), and the specificity (around 65%) is greatly improved after the biopsies are read, distinguishing between esophagitis and dysplasia.

Table 2. Comparison of risk factors evaluated for ESCC and esophageal squamous dysplasia in China

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>ESCC (Ref. no.)</th>
<th>Dysplasia (Linxian) (Ref. no.)</th>
<th>Dysplasia (Anyang) (Ref. no.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>No (44)</td>
<td>No (60)</td>
<td>No (58)</td>
</tr>
<tr>
<td>Tobacco smoking</td>
<td>Yes (44, 45)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol drinking</td>
<td>No (44, 45)</td>
<td>No (60)</td>
<td>No (58)</td>
</tr>
<tr>
<td>Family history of cancer</td>
<td>Yes (44)</td>
<td>Yes (60)</td>
<td>NA^</td>
</tr>
<tr>
<td>Tooth loss</td>
<td>Yes^b</td>
<td>Yes (60)</td>
<td>No (58)</td>
</tr>
<tr>
<td>Serum vitamin D</td>
<td>Yes^c</td>
<td>Yes (61)</td>
<td>NA</td>
</tr>
<tr>
<td>Water source</td>
<td>Yes (44)</td>
<td>NA</td>
<td>Yes (58)</td>
</tr>
<tr>
<td>Serum pepsinogens</td>
<td>No^d</td>
<td>Yes (62)</td>
<td>NA</td>
</tr>
<tr>
<td>Hot liquids/food</td>
<td>No (44) and yes (45)</td>
<td>NA</td>
<td>No (58)</td>
</tr>
<tr>
<td>HPV</td>
<td>No (65–67) and yes (63–64, 68, 70, 71)</td>
<td>No (69) and yes (70, 71)</td>
<td>Yes (63)</td>
</tr>
</tbody>
</table>

^NA: information not available.

Without Lugol’s
With Lugol’s

Figure 4. Esophageal squamous dysplasia without and with Lugol’s iodine staining. An unstained lesion becomes readily apparent after topical application of Lugol’s iodine solution which can then be targeted for biopsy.
Natural history of dysplasia

The natural history of ESD has not been extensively studied, but some observations bearing on the progression of these lesions have been reported. As noted earlier, follow-up of untreated patients in a high-risk Chinese population with biopsy-proven mild, moderate, and severe squamous dysplasia showed development of clinically diagnosed ESCC in 5%, 27%, and 65% after 3.5 years (4) and 24%, 50%, and 74% after 13.5 years (5). Another report of patients with moderate or severe dysplasia who were followed endoscopically for 16 months found that 22% with moderate dysplasia and 60% with severe dysplasia showed endoscopic (size) or histologic progression during this period (77). No similar follow-up studies of untreated patients with ESD have been reported from Western populations. Thus, at least in China, ESD seems to progress over months to many years, depending on the grade. But based on the high cumulative incidence figures reported above, it is probable that severe dysplasia needs prompt treatment, moderate dysplasia needs treatment or periodic endoscopic follow-up, and mild dysplasia can be followed at longer intervals. There is a need for more studies evaluating the natural history of ESD, and a need for consensus clinical guidelines for treatment and patient follow-up after treating these lesions.

Treatment of dysplasia

Several endoscopic methods are used to treat ESD. Excisional methods, in which the lesion is excised endoscopically, include endoscopic mucosal resection (EMR) using the "cap method" (78), EMR using the "banding method" (also called multiband mucosectomy, or MBM; ref. 79), and endoscopic submucosal dissection (78, 80). Ablative methods, which burn the lesions in situ, include multipolar electrocoagulation (MPEC), argon plasma coagulation (APC), and radiofrequency ablation (RFA; ref. 76). An advantage of the excisional methods is the ability to provide a histologic diagnosis (also called multiband mucosectomy, or MBM; ref. 79), and EMR using the "banding method" (also called multiband mucosectomy, or MBM; ref. 79), and endoscopic submucosal dissection (78, 80). Ablative methods, which burn the lesions in situ, include multipolar electrocoagulation (MPEC), argon plasma coagulation (APC), and radiofrequency ablation (RFA; ref. 76). An advantage of the excisional methods is the preservation of the lesion in a surgical specimen, which can be reviewed pathologically to document the true extent of disease and evaluate the need for additional therapy, but a disadvantage is that they require greater endoscopic expertise to perform. All of these treatment methods are relatively new in high-risk areas, so the optimal clinical follow-up protocols are still being defined and the procedural costs and cost-benefit comparisons are still being evaluated.

Prospects and Implications for Prevention

Target and strategy

Dysplasia, the ESCC precursor lesion, is a target for prevention strategies, including both chemoprevention and screening, even though there is not yet a strategy in place.

Chemoprevention

Chemoprevention emerged as a cancer prevention strategy in the 1980s, and ESCC was a target for prevention in 2 early nutrition intervention trials conducted in China. Results from those trials showed that supplementation with the combination of selenium/vitamin E/b-carotene reduced total mortality, total cancer mortality, and gastric cancer mortality and incidence in the Linxian General Population NIT, but no benefit was seen for esophageal cancer (48). No effect was seen on esophageal cancer incidence or mortality from multivitamin supplementation in the Linxian Dysplasia NIT (81). The beneficial effects of selenium/vitamin E/b-carotene on mortality were still evident up to 10 years after the cessation of supplementation in the Linxian General Population NIT, and reduced esophageal cancer mortality was also seen then among younger participants (82).

There have been many more trials evaluating precursor and precursor-related lesions of the squamous esophagus than there have been trials with actual cancer endpoints. As with the cancer endpoint-based prevention trials, these precursor trials have all been conducted in northern China. A total of 13 analyses (summarized in Table 3) have been published from 10 different interventions (83–94). All but 2 of the trials evaluated a nutritional intervention, including a variety of micronutrients (e.g., retinol, riboflavin, zinc, calcium, selenium, multivitamins, etc.), decaffeinated green tea, and freeze-dried strawberries, whereas a single trial evaluated antitumor B (a mixture of 6 Chinese herbs) and a retinoid (95), and another tested celecoxib (92). Trial endpoints were typically histologic or cytologic regression or progression, or prevalence of dysplasia, with a few reports of other intermediate endpoint markers (e.g., prevalence of micronuclei or proliferation markers). Evidence for a beneficial effect on premalignancy was observed in 4 of these studies: the combination of retinol+riboflavin+zinc reduced micronuclei (84); multivitamins improved cytology (90); selenomethionine improved histology (92); and strawberries improved histology and reduced proliferation and expression of several cancer-related proteins (94). A benefit for cancer was observed for antitumor B (85) and riboflavin (85) and was suggested among persons whose communities received riboflavin-fortified salt (93).

Use of screening

The determination that ESD is the preneoplastic lesion for ESCC provides the possibility of screening not just for early stage ESCC, but also to screen for and treat the preneoplastic lesion itself in a manner analogous to screening and treating cervical dysplasia to prevent cervical cancer. A comprehensive system that uses chromoendoscopy and grade-specific therapy for ESD has the potential to reduce disease incidence and disease-specific mortality. In areas with very high rates of the disease it could even reduce total mortality. A community assignment trial in a high-incidence region of China has shown that endoscopic screening and treatment reduced esophageal cancer incidence and mortality (Unpublished Data). But like all screening methodologies, the use of this regimen remains speculative without confirmatory randomized trial data that prove that this method is beneficial.
Table 3. Chemoprevention trials evaluating precursor and precursor-related lesions of the squamous esophagus in north China

<table>
<thead>
<tr>
<th>Year reported</th>
<th>Authors (Ref. no.)</th>
<th>Location</th>
<th>Population</th>
<th>Design</th>
<th>Intervention</th>
<th>Duration</th>
<th>Endpoint(s)</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>1985</td>
<td>Munoz and colleagues (83)</td>
<td>Huixian</td>
<td>N = 610 35-64 y</td>
<td>2-Arm RCT&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Retinol + riboflavin + zinc (vs. placebo)</td>
<td>13.5 mo</td>
<td>Esophagitis (histo)</td>
<td>No effect</td>
</tr>
<tr>
<td>1987</td>
<td>Munoz and colleagues (84)</td>
<td>Huixian</td>
<td>N = 200 35-64 y</td>
<td>2-Arm RCT</td>
<td>Retinol + riboflavin + zinc (vs. placebo)</td>
<td>13.5 mo</td>
<td>Micronuclei in esophageal cells (histo)</td>
<td>Benefit (Intervention 0.19% vs. placebo 0.31%)</td>
</tr>
<tr>
<td>1988</td>
<td>Lin and colleagues (85)</td>
<td>Heshun, Linxian</td>
<td>N = 1,728 severe dysplasia</td>
<td>3-Arm RCT</td>
<td>Antitumor B, Retinamide (vs. placebo)</td>
<td>3 y</td>
<td>Cytology regress/progress</td>
<td>No effect for antitumor B&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1988</td>
<td>Lin and colleagues (85)</td>
<td>Heshun, Linxian</td>
<td>N = 2,412 mild dysplasia</td>
<td>2-Arm RCT</td>
<td>Riboflavin (vs. placebo)</td>
<td>3 y</td>
<td>Cytology regress/progress</td>
<td>No effect&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>1993</td>
<td>Wang and colleagues (86)</td>
<td>Huixian</td>
<td>N = 200 non-normal 30-60 y</td>
<td>2-Arm RCT</td>
<td>Calcium (vs. placebo)</td>
<td>11 mo</td>
<td>Histology regress/progress</td>
<td>No effect on histology</td>
</tr>
<tr>
<td>1994</td>
<td>Wang and colleagues (87)</td>
<td>Linxian</td>
<td>N = 391 40-69 y</td>
<td>2 × 4 Fractional factorial RCT</td>
<td>4 Micronutrient groups/factors</td>
<td>5.25 y</td>
<td>Dysplasia/progress cancer (histo)</td>
<td>No effect on proliferation for any of 4 factors</td>
</tr>
<tr>
<td>1994</td>
<td>Dawsey and colleagues (88)</td>
<td>Linxian</td>
<td>N = 833 and 396 dysplasia 40-69 y</td>
<td>2-Arm RCT</td>
<td>Multivitamins (vs. placebo)</td>
<td>2.5 and 6 y</td>
<td>Dysplasia/cancer (histo)</td>
<td>No effect at either time point</td>
</tr>
<tr>
<td>1994</td>
<td>Rao and colleagues (89)</td>
<td>Linxian</td>
<td>N = 512 dysplasia 40-69 y</td>
<td>2-Arm RCT</td>
<td>Multivitamins (vs. placebo)</td>
<td>2.5 y</td>
<td>Proliferation (histo)</td>
<td>No effect overall</td>
</tr>
<tr>
<td>1994</td>
<td>Mark and colleagues (90)</td>
<td>Linxian</td>
<td>N = 3,318 dysplasia 40-69 y</td>
<td>2-Arm RCT</td>
<td>Multivitamins (vs. placebo)</td>
<td>2.5 and 6 y</td>
<td>Cytology regress/progress</td>
<td>Benefit (Intervention OR for regression to nondysplasia = 1.23)</td>
</tr>
<tr>
<td>2002</td>
<td>Wang and colleagues (91)</td>
<td>Huixian</td>
<td>N = 200 non-normal 30-60 y</td>
<td>2-Arm RCT</td>
<td>Decaffeinated green tea (vs. placebo)</td>
<td>12 mo</td>
<td>Histology regress/progress</td>
<td>No effect</td>
</tr>
<tr>
<td>2005</td>
<td>Limburg and colleagues (92)</td>
<td>Linxian</td>
<td>N = 238 dysplasia 34-68 y</td>
<td>2 × 2 Factorial RCT</td>
<td>Selenomethionine, Celecoxib</td>
<td>11 mo</td>
<td>Histology regress/progress</td>
<td>Benefit in mild dysplasia (Selenomethionine increased regression &amp; decreased progression = 2-fold each)</td>
</tr>
</tbody>
</table>

(Continued on the following page)
<table>
<thead>
<tr>
<th>Year reported</th>
<th>Authors (Ref. no.)</th>
<th>Location</th>
<th>Population</th>
<th>Design</th>
<th>Intervention</th>
<th>Duration</th>
<th>Endpoint(s)</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>He and colleagues (93)</td>
<td>Cixian</td>
<td>N = 9 townships (11,392 persons) fortified vs. 12 townships (10,711 persons) unfortified</td>
<td>Endoscopy comparison of 950 fortified vs. 1,300 unfortified group persons 40-69 y (randomly selected)</td>
<td>Riboflavin-fortified salt (vs. unfortified salt)</td>
<td>6 y</td>
<td>Dysplasia (histo) Cancer (histo)</td>
<td>No effect on dysplasia Suggested benefit for cancer (Intervention 1.6% vs. placebo 3.1%)</td>
</tr>
<tr>
<td>2011</td>
<td>Chen and colleagues (94)</td>
<td>Henan, Shandong</td>
<td>N = 75 dysplasia</td>
<td>37 low dose, 38 high dose (randomized to dose group)</td>
<td>Freeze-dried strawberries (low, high doses)</td>
<td>6 mo</td>
<td>Histology regress/progress Proliferation Protein expression</td>
<td>Benefit for high dose (reduced histology grade in 81%) Benefit for high dose (reduced Ki-67 labeling by 38%) Benefit for high dose (reduced iNOS 80%, COX-2 63%, NF-κB-p65 63%, pS6 73%)</td>
</tr>
</tbody>
</table>

aRCT, randomized controlled trial.
bNeither antitumor B nor retinamide improved cytology regression/progression overall, but antitumor B reduced the number of new cancers (3.9% for antitumor B group vs. 8.3% for placebo group).
cRiboflavin did not improve cytology regression/progression overall but reduced the number of new cancers (1.7% for riboflavin group vs. 2.1% for placebo group).
because there is clear evidence that early detection of cancer is not always beneficial because not all preneoplastic lesions progress and treatments may cause serious complications and side effects (96).

Furthermore, populations with high incidence rates of esophageal cancer tend to be poor and medically underserved. Endoscopic screening and treatment of an entire population would be expensive and would require many highly trained physicians and expensive equipment. Risk stratification to reduce the number of people needing screening would be useful, but this remains impractical based on demographic and easily collected exposure variables (59, 60). Alternatively, a simpler primary screening test that identifies subjects most likely to be positive for ESD could reduce the number of individuals needing endoscopic screening. Previous attempts to use balloon cytology (analogous to a Pap smear) to find subjects with ESD showed that this method was likely too insensitive and nonspecific to be useful for full-scale screening (55, 57). But improved molecular testing of nonendoscopically retrieved esophageal cells has shown promise for screening for the EAC precursor, Barrett’s esophagus (97), and may facilitate ESD screening as well.

Summary

ESCC is the predominant form of esophageal cancer worldwide, particularly in developing countries, and has among the poorest survival of all cancers. ESCC is the precursor lesion for ESCC and the prevalence of ESCD is 25% or more among adults in areas of north central China where ESCC rates are highest. Risk factors for ESD seem largely to parallel those of invasive ESCC. The high prevalence of ESD in high-risk areas, coupled with simple but sensitive endoscopic-based methods to detect dysplasia, suggest that early detection of persons with precursor lesions for subsequent prevention strategies such as chemoprevention or endoscopic therapy offer substantial promise for the reduction of ESCC mortality. Future research on ESD and ESCC should focus on finding additional modifiable risk factors and on identifying biomarkers to incorporate into patient-acceptable early detection strategies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: P.R. Taylor, C.C. Abnet, S.M. Dawsey
Development of methodology: P.R. Taylor, S.M. Dawsey
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.R. Taylor, S.M. Dawsey
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P.R. Taylor, C.C. Abnet, S.M. Dawsey
Writing, review, and/or revision of the manuscript: P.R. Taylor, C.C. Abnet, S.M. Dawsey
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P.R. Taylor
Study supervision: P.R. Taylor, S.M. Dawsey

Received December 4, 2012; revised February 11, 2013; accepted February 13, 2013; published online April 2, 2013.

References


Squamous Dysplasia—The Precursor Lesion for Esophageal Squamous Cell Carcinoma

Philip R. Taylor, Christian C. Abnet and Sanford M. Dawsey


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/22/4/540

Cited articles
This article cites 96 articles, 21 of which you can access for free at:
http://cebp.aacrjournals.org/content/22/4/540.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/22/4/540.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.